

Substitute for form 1449/PTO



**COMPLETE IF KNOWN**

Application Number	10/648593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1656
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet 1 of 3**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Baselga, et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 <sup>HER2</sup> Monoclonal Antibody in Patients with HER2/ <i>neu</i> -Overexpressing Metastatic Breast Cancer", J. Clin. Oncol., Vol. 14(3), pp. 737-744 (1996)	
	AB	Bild, et al., "Oncogenic Pathway Signatures in Human Cancers as a Guide to Targeted Therapies", Nature, Vol. 439, pp. 353-357 (2006)	
	AC	Brenton, et. al., "Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?", J. Clin. Oncol., Vol. 23(29), pp. 7350-7360 (2005)	
	AD	Burgess, et al., "Comparative Analysis of Two Clinically Active BCR-ABL Kinase Inhibitors Reveals the Role of Conformation-Specific Binding in Resistance", PNAS, Vol. 102, pp. 3395-3400 (2005)	
	AE	Carlini, et al., "UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan", Clin. Can. Res., Vol. 11, pp. 1226-1236 (2005)	
	AF	Dressman, et al., "Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy", Clin. Can. Res., Vol. 12(3), pp. 819-826 (2006)	
	AG	Duxbury, et al., "CEACAM6 Cross-linking Induces Caveolin-1-dependent, Src-mediated Focal Adhesion Kinase Phosphorylation in BxPC3 Pancreatic Adenocarcinoma Cells", J. Biol. Chem., Vol. 279(22), pp. 23176-23182 (2004)	
	AH	Biscardi, et al., "c-SRC, Receptor Tyrosine Kinases, and Human Cancer", Adv. Can. Res., Vol. 9(6), pp. 61-119 (1999)	
	AI	Eliceiri, et al., "Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability", Molec. Cell, Vol. 4, pp. 915-924 (1999)	
	AJ	Finn, et al., "Biologic Effects and Identification of Predictive Markers of Response to Dasatinib (BMS-354825), a Novel, Oral, Multi-targeted Kinase Inhibitor in Human Breast Cancer Cell Lines <i>in vitro</i> ", Clin. Can. Res., Vol. 11(24), pp. 9022s (2005)	
	AK	Giancotti, et al., "Integrin Signaling", Science, Vol. 285, pp. 1028-1032 (1999)	
	AL	Horne, et al., "The Role(s) of Src Kinase and Cbl Proteins in the Regulation of Osteoclast Differentiation and Function", Immunol. Rev., Vol. 208, pp. 106-125 (2005)	
	AM	Iwao-Koizumi, et al., "Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling", J. Clin. Oncol., Vol. 23(3), pp. 422-431 (2005)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

SHERIDAN SWOPE, PH.D.  
PRIMARY EXAMINER

NOV 24 2006

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet

2



of

3

**COMPLETE IF KNOWN**

Application Number	10/648,593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1656
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	2AA	Johnson, et al., "Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer Cells", Clin. Can. Res., Vol. 11(19), pp. 6924-6932 (2005)	
	2AB	Landen, et al., "EphA2 as a Target for Ovarian Cancer Therapy", Expert Opin. Ther. Targets, Vol. 9(6), pp. 1179-1187 (2005)	
	2AC	Lynch, et al., "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib", New Engl. J. Med., Vol. 350(21), pp. 2129-2139 (2004)	
	2AD	Mao, et al., "Activation of c-Src by Receptor Tyrosine Kinases in Human Colon Cancer Cells with High Metastatic Potential", Oncogene, Vol. 15, pp. 3083-3090 (1997)	
	2AE	Mariadason, et. al., "Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin", Can. Res., Vol. 63, pp. 8791-8812 (2003)	
	2AF	Myoui, et al., "C-Src Tyrosine Kinase Activity Is Associated with Tumor Colonization in Bone and Lung in an Animal Model of Human Breast Cancer Metastasis", Can. Res., Vol. 63, pp. 5028-5033 (2003)	
	2AG	Nam, et al., "Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells", Can. Res., Vol. 65(20), pp. 9185-9189 (2005)	
	2AH	Pao, et al., "EGF Receptor Gene Mutations are Common in Lung Cancers from 'Never Smokers' and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib", PNAS, Vol. 101, pp. 13306-13311 (2004)	
	2AI	Pawitan, et al., "Gene Expression Profiling Spares Early Breast Cancer Patients from Adjuvant Therapy: Derived and Validated in Two Population-Based Cohorts", Breast Can. Res., Vol. 7, pp. R953-R964 (2005)	
	2AJ	Perou, et al., "Molecular Portraits of Human Breast Tumours", Nature, Vol. 406, pp. 747-752 (2000)	
	2AK	Peters, et al., "Genome-wide Transcriptional Analysis of Carboplatin Response in Chemosensitive and Chemoresistant Ovarian Cancer Cells", Mol. Can. Ther., Vol. 4(10), pp. 1605-1616 (2005)	
	2AL	Roberts, et al., "Identification of Genes Associated with Platinum Drug Sensitivity and Resistance in Human Ovarian Cancer Cells", Brit. J. Can., Vol. 92, pp. 1149-1158 (2005)	
	2AM	Rouzier, et al., "Microtubule-associated Protein Tau: A Marker of Paclitaxel Sensitivity in Breast Cancer", PNAS, Vol. 102, pp. 8315-8320 (2005)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not

Examiner Signature	SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER	Date Considered	NOV 24 2006
-----------------------	---	--------------------	-------------

considered. Include a copy of this form with the next communication to applicant

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT(S)**



(use as many sheets as necessary)

**COMPLETE IF KNOWN**

Application Number	10/648,593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1656
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	3AA	Shah, et al., "Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor", Science, Vol. 305, pp. 399-401 (2004)	
	3AB	Shah, et al., "BMS-354825: a Novel Drug with Potential for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia", Expert Opin. Investig. Drugs, Vol. 14(1), pp. 89-91 (2005)	
	3AC	Staunton, et al., "Chemosensitivity Prediction by Transcriptional Profiling", PNAS, Vol. 98, pp. 10787-10792 (2001)	
	3AD	Susa, et al., "Src Inhibitors: Drugs for the Treatment of Osteoporosis, Cancer or Both", TIPS, Vol. 21, pp. 489-495 (2000)	
	3AE	Talpaz, et al., "Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias", N. Engl. J. Med., Vol. 354, pp. 2531-2541 (2006)	
	3AF	Thomas, et al., "Cellular Functions Regulated by SRC Family Kinases", Annu. Rev. Cell Dev. Biol., Vol. 13, pp. 513-609 (1997)	
	3AG	Van de Rijn, et al., "Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome", Am. J. Path., Vol. 161(6), pp. 1991-1996 (2002)	
	3AH	Vekris, et al., "Molecular Determinants of the Cytotoxicity of Platinum Compounds: The Contribution of <i>in Silico</i> Research", Can. Res., Vol. 64, pp. 356-362 (2004)	
	3AI	Verbeek, et al., "c-Src Protein Expression is Increased in Human Breast Cancer. An Immunohistochemical and Biochemical Analysis", J. Path., Vol. 180, pp. 383-388 (1996)	
	3AJ	Warmuth, et al., "Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia", Curr. Pharm. Design, Vol. 9, pp. 2043-2059 (2003)	
	3AK	Weis, et al., "Endothelial Barrier Disruption by VEGF-Mediated Src Activity Potentiates Tumor Cell Extravasation and Metastasis", J. Cell Biol., Vol. 167(2), pp. 223-229 (2004)	
	3AL	Yamanashi, et al., "The yes-Related Cellular Gene <i>lyn</i> Encodes a Possible Tyrosine Kinase Similar to p56 <sup>lck</sup> ", Molec. Cell. Biol., Vol. 7(1), pp. 237-243 (1987)	

SHERIDAN SWOPE, PH.D.


PRIMARY EXAMINER

NOV 24 2006

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.  
D0273 NP  
APPLICATION NO.  
10/648,593  
APPLICANT  
HUANG ET AL.  
FILING DATE  
AUGUST 26, 2003Group  
1656

Use several sheets if necessary

## U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
AS	AA	10/348,119	1/17/03	Huang, et al.			
	AB	11/169,041	6/28/05	Huang, et al.			

## U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
AS	AC	2006/0029971 A1	2/9/06	Golub, et al.			
	AD	2005/0079518 A1	4/14/05	Baker, et al.			

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AS	AG	WO00/62778	10/26/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AS	AL	Aasheim, et al., "A Splice Variant of Human Ephrin-A4 Encodes a Soluble Molecule that is Secreted by Activated Human B Lymphocytes", Blood, Vol. 95(1), pp. 221-230 (2000)
	AM	Abraham, et al., "Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder", Clin. Cancer Res., Vol. 12(2), pp. 353-360 (2006)
	AN	Alves, et al., "EphA2 as Target of Anticancer Immunotherapy: Identification of HLA-A*0201-Restricted Epitopes", Cancer Res., Vol. 63, pp. 8476-8480 (2003)

EXAMINER

SHERIDAN SWOPE, PH.D.  
PRIMARY EXAMINER

DATE CONSIDERED

NOV 24 2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0273 NP  
APPLICATION NO.  
10/648,593  
APPLICANT  
HUANG ET AL.  
FILING DATE  
AUGUST 26, 2003Group  
1656

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Blume-Jensen, et al., "Oncogenic Kinase Signalling", Nature, Vol. 411, pp. 355-365 (2001)
2AB	Brantley, et al., "Soluble Eph A Receptors Inhibit Tumor Angiogenesis and Progression <i>in vivo</i> ", Oncogene, Vol. 21, pp. 7011-7026 (2002)
2AC	Brown, et al., "Regulation, Substrates and Functions of SRC", Biochimica et Biophys. Acta., Vol. 1287, pp. 121-149 (1996)
2AD	Cheng, et al., "Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis", Molec. Cancer Res., Vol. 1, pp. 2-11 (2002)
2AE	Davis, et al., "Ligands for EPH-Related Receptor Tyrosine Kinases That Require Membrane Attachment or Clustering for Activity", Science, Vol. 266, pp. 816-819 (1994)
2AF	de Saint-Vis, et al., "Human Dendritic Cells Express Neuronal Eph Receptor Tyrosine Kinases: Role of EphA2 in Regulating Adhesion to Fibronectin", Blood, Vol. 102(13), pp. 4431-4440 (2003)
2AG	Duxbury, et al., "Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness", Biochem. Biophysical Res. Comm., Vol. 320, pp. 1096-1102 (2004)
2AH	Fang, et al., "A Kinase-Dependent Role for EphA2 Receptor in Promoting Tumor Growth and Metastasis", Oncogene, Vol. 24, pp. 7859-7868 (2005)
2AI	Flanagan, et al., "The Ephrins and EPH Receptors in Neural Development", Annu. Rev. Neurosci, Vol. 21, pp. 309-45 (1998)
2AJ	Frame, M.C., "Src in Cancer: Deregulation and Consequences for Cell Behaviour", Biochimica et Biophys. Acta, Vol. 1602, pp. 114-130 (2002)
2AK	Gale, et al., "Eph Receptors and Ligands Comprise Two Major Specificity Subclasses and Are Reciprocally Compartmentalized during Embryogenesis", Neuron, Vol. 17, pp. 9-19 (1996)
2AL	Ganju, et al., "The Eck Receptor Tyrosine Kinase is Implicated in Pattern Formation during Gastrulation, hindbrain segmentation and limb development", Oncogene, Vol. 9, pp. 1613-1624 (1994)
2AM	Goldman-Wohl, et al., "Eph and Ephrin Expression in Normal Placental Development and Preeclampsia", Placenta, Vol. 25, pp. 623-630 (2004)
2AN	Herath, et al., "Over-Expression of Eph and Ephrin Genes in Advanced Ovarian Cancer: Ephrin Gene Expression Correlates with Shortened Survival", BMC Cancer, Vol. 6, pp. 144 (2006)

EXAMINER

SHERIDAN SWOPE, PH.D.  
PRIMARY EXAMINER

DATE CONSIDERED

NOV 24 2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0273 NP  
APPLICATION NO.  
10/648,593  
APPLICANT  
HUANG ET AL.  
FILING DATE  
AUGUST 26, 2003

Sheet 3 of 6

Group  
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Herrem, et al., "Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma", Vol. 11, pp. 226-231 (2005)
3AB	Hess, et al., "VE-Cadherin Regulates EphA2 in Aggressive Melanoma Cells Through a Novel Signaling Pathway", Cancer Biol. Therapy, Vol. 5(2), pp. 228-233 (2006)
3AC	Holder, et al., "Eph Receptors and Ephrins: Effectors of Morphogenesis", Development, Vol. 126, pp. 2033-2044 (1999)
3AD	Hu, et al., "EphA2 Induction of Fibronectin Creates a Permissive Microenvironment for Malignant Cells", Mol Cancer Res., Vol. 2(10), pp. 533-540 (2004)
3AE	Hynes, N.E., "Tyrosine Kinase Signalling in Breast Cancer", Breast Cancer Res., Vol. 2, pp. 154-157 (2000)
3AF	Kalo, et al., "Signal Transfer by Eph Receptors", Cell Tissue Res., Vol. 298, pp. 1-9 (1999)
3AG	Kataoka, et al., "Correlation of EPHA2 Overexpression with High Microvessel Count in Human Primary Colorectal Cancer", Cancer Sci., Vol. 95(2), pp. 136-141 (2004)
3AH	Kikawa, et al., "Regulation of the EphA2 Kinase by the Low Molecular Weight Tyrosine Phosphatase Induces Transformation", J. Biol. Chem., Vol. 277(42), pp. 39274-39279 (2002)
3AI	Kinch, et al., "Overexpression and Functional Alterations of the EphA2 Tyrosine Kinase in Cancer", Clin. Exper. Metastasis, Vol. 20, pp. 59-68 (2003)
3AJ	Kinch, et al., "Predictive Value of the EphA2 Receptor Tyrosine Kinase in Lung Cancer Recurrence and Survival", Clin. Cancer Res., Vol. 9, pp. 613-618 (2003)
3AK	Koolpe, et al., "An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor", J. Biol. Chem., vol. 277(49), pp. 46974-46979 (2002)
3AL	Kozlosky, et al., "Lerk-7: A Ligand of the Eph-Related Kinases is Developmentally Regulated in the Brain", Cytokine, Vol. 9(8), pp. 540-549 (1997)
3AM	Lindberg, et al., "cDna Cloning and Characterization of eck, an Epithelial Cell Receptor Protein-Tyrosine Kinase in the eph/elk Family of Protein Kinases", Molec. Cell. Biol., Vol. 10(12), pp. 6316-6324 (1990)
3AN	Lombardo, et al., "Discovery of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide(BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays", J. Med. Chem., Vol. 47, pp. 6658-6661 (2004)

EXAMINER

PRIMARY EXAMINER

DATE CONSIDERED

NOV 24 2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0273 NP  
APPLICATION NO.  
10/648,593  
APPLICANT  
HUANG ET AL.  
FILING DATE  
AUGUST 26, 2003Group  
1656

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

88	4AA	Lu, et al., "EphA2 Overexpression Decreases Estrogen Dependence and Tamoxifen Sensitivity", Cancer Res., Vol. 63, pp. 3425-3429 (2003)
	4AB	Macrae, et al., "A Conditional Feedback Loop Regulates Ras Activity Through EphA2", Cancer Cell, Vol. 8, pp. 111-118 (2005)
	4AC	Miao, et al., "Activation of EphA2 Kinase Suppresses Integrin Function and Causes Focal-Adhesion-Kinase Dephosphorylation", Nature Cell Biol., Vol. 2, pp. 62-69 (2000)
	4AD	Miyazaki, et al., "EphA2 Overexpression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma", Int. J. Cancer, Vol. 103, pp. 657-663 (2003)
	4AE	Nakamoto, et al., "Diverse Roles for the Eph Family of Receptor Tyrosine Kinases in Carcinogenesis", Microscopy Research Tech., Vol. 59, pp. 58-67 (2002)
	4AF	Nakamura, et al., "Epha2/Efna1 Expression in Human Gastric Cancer", Cancer Sci., Vol. 96(1), pp. 42-47 (2005)
	4AG	Ogawa, et al., "The Ephrin-A1 Ligand and its Receptor, EphA2, are Expressed during Tumor Neovascularization", Oncogene, Vol. 19, pp. 6043-6052 (2000)
	4AH	Paik, et al., "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer", New Eng. J. Med., Vol. 351(27), pp. 2817-2826 (2004)
	4AI	Pandey, et al., "Characterization of a Novel Src-like Adapter Protein That Associates with the Eck Receptor Tyrosine Kinase", Vol. 270(33), pp. 19201-19204 (1995)
	4AJ	Pandey, et. al., "Activation of the Eck Receptor Protein Tyrosine Kinase Stimulates Phosphatidylinositol 3-Kinase Activity", J. Biol. Chem., Vol. 269(48), pp. 30154-30157 (1994)
	4AK	Pandey, et. al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- $\alpha$ -Induced Angiogenesis", Science, Vol. 268, pp. 567-569 (1995)
	4AL	Parri, et. al., "EphrinA1 Repulsive Response is Regulated by an EphA2 Tyrosine Phosphatase", J. Biol. Chem., Vol. 280(40), pp. 34008-34018 (2005)
	4AM	Pratt, et al., "Activation of the EphA2 Tyrosine Kinase Stimulates the MAP/ERK Kinase Signaling Cascade", Oncogene, Vol. 21, pp. 7690-7699 (2002)
1	4AN	Riss, et al., "Comparison of MTT, XTT, and Novel Letrazollum Compound MTS for In Vitro Proliferation and Chamosensitivity Assays", Mol. Biol. Cell, 3 (Suppl):184(a).

EXAMINER

SHERIDAN SWOPE, PH.D.  
PRIMARY EXAMINER

DATE CONSIDERED

NOV 24 2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0273 NP  
APPLICATION NO.  
10/648,593  
APPLICANT  
HUANG ET AL.  
FILING DATE  
AUGUST 26, 2003Group  
1656

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

88	5AA	Ruiz, et al., "The Expression of the Receptor-Protein Tyrosine Kinase Gene, <i>Eck</i> , is Highly Restricted during Early Mouse Development", Mechanisms Develop., Vol. 46, pp. 87-100 (1994)
	5AB	Saito, et al., "Expression of EphA2 and E-Cadherin in Colorectal Cancer: Correlation with Cancer Metastasis", Oncology Rep., Vol. 11, pp. 605-61 (2004)
	5AC	Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, /First and Second Edition, Book 1, Cold Spring Harbor Laboratory Press, publ., pp. 1.93-1.104 (1989)
	5AD	Sulman, et al., "ECK, a Human EPH-Related Gene, Maps to 1p36.1, a Common Region of Alteration in Human Cancers", Genomics, Vol. 40, pp. 371-374 (1997)
	5AE	Tanaka, et al., "EphA2 Phosphorylates the Cytoplasmic Tail of Claudin-4 and Mediates Paracellular Permeability", J. Biol. Chem., Vol. 280(51), pp. 42375-42382 (2005)
	5AF	Thaker, et al., "EphA2 Expression is Associated with Aggressive Features in Ovarian Carcinoma", Clin. Cancer Res., Vol. 10, pp. 5145-5150 (2004)
	5AG	Walker-Daniels, et al., "Differential Regulation of EphA2 in Normal and Malignant Cells", Amer. J. Path., Vol. 162(4), pp. 1037-1042 (2003)
	5AH	Walker-Daniels, et al., "C-Cbl-Dependent EphA2 Protein Degradation is Induced by Ligand Binding", Molecular Cancer Res., Vol. 1, pp. 79-87 (2002)
	5AI	Wands, et al., "High Affinity Monoclonal Antibodies to Hepatitis B Surface Antigen (HB <sub>s</sub> Ag) Produced by Somatic Cell Hybrids", Gastroenterology, Vol. 80, pp. 225-32 (1981)
	5AJ	Wang, et al., "Negative Regulation of EphA2 Receptor by Cbl", Biochem. Biophys. Res. Comm., Vol. 296, pp. 214-220 (2002)
	5AK	Wilkinson, D.G., "Eph Receptors and Ephrins: Regulators of Guidance and Assembly", International Rev. Cytology, Vol. 196, pp. 177-244 (2000)
	5AL	Wilkinson, D.G., "Multiple Roles of EPH Receptors and Ephrins in Neural Development", Vol. 2, pp. 155-164 (2001)
	5AM	Xu, et al., "EphA2: Expression in the Renal Medulla and Regulation by Hypertonicity and Urea Stress In Vitro and In Vivo", Am. J. Physiol. Renal Physiol, Vol. 288, pp. F855-F866 (2005)
X	5AN	Xu, et al., "Roles of Eph Receptors and Ephrins in Segmental Patterning", Phil. Trans. R. Soc. Lond., B., Vol. 355, pp. 993-1002 (2000)

EXAMINER

SHERIDAN SWOPE, PH.D.  
PRIMARY EXAMINER

DATE CONSIDERED

NOV 24 2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0273 NP  
APPLICATION NO.  
10/648,593  
APPLICANT  
HUANG ET AL.  
FILING DATE  
AUGUST 26, 2003

Group  
1656

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

85	6AA	Yong, et al., "Molecular Profiling of CD34+ Cells Identifies Low Expression of CD7, Along with High Expression of Proteinase 3 or Elastase, as Predictors of Longer Survival in Patients with CML", Blood, Vol. 107(1), pp. 205-212 (2006)
	6AB	Zelinski, et al., "Estrogen and Myc Negatively Regulate Expression of the EphA2 Tyrosine Kinase", J. Cell. Biochem., Vol. 85, pp. 714-720 (2002)
	6AC	Zeng, et al., "High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia", Amer. J. Path., Vol. 163(6), pp. 2271-2276 (2003)
	6AD	Zhou, R., "The Eph Family Receptors and Ligands", Pharmacol. Ther., Vol. 77(3), pp. 151-181 (1998)
	6AE	NCBI Entrez Accession No. NM_004431 (gi:32967310), Hess, et al., August 13, 2006
	6AF	
	6AG	
	6AH	
	6AI	
	6AJ	
	6AK	
	6AL	
	6AM	
	6AN	

EXAMINER

SHERIDAN SWOPE, PH.D.  
PRIMARY EXAMINER

DATE CONSIDERED

NOV 24 2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.